Peter T. Silberstein

Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy

Thomas E. Witzig, Peter T. Silberstein, Charles L. Loprinzi et al. · Journal of Clinical Oncology · 2004 · 209 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7

Axel Grothey, Daniel A. Nikcevich, Jeff A. Sloan et al. · Journal of Clinical Oncology · 2010 · 197 citations · Full text

Medicine, Oncology, Pharmacology +17

Controlled‐release oxycodone compared with controlled‐release morphine in the treatment of cancer pain: A randomized, double‐blind, parallel‐group study

Patricia Mucci‐LoRusso, Barry S. Berman, Peter T. Silberstein et al. · European Journal of Pain · 1998 · 175 citations

Nursing, Pharmacology, Pharmacotherapy +17

Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Long-Acting Methylphenidate for Cancer-Related Fatigue: North Central Cancer Treatment Group NCCTG-N05C7 Trial

Amanda R. Moraska, Amit Sood, Shaker R. Dakhil et al. · Journal of Clinical Oncology · 2010 · 172 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous Iron in patients with chemotherapy‐induced anemia

Michael Auerbach, Peter T. Silberstein, R. Timothy Webb et al. · American Journal of Hematology · 2010 · 89 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13